Compare PBT & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBT | OMER |
|---|---|---|
| Founded | 1980 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 844.6M |
| IPO Year | N/A | 2008 |
| Metric | PBT | OMER |
|---|---|---|
| Price | $35.32 | $17.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 88.1K | ★ 1.5M |
| Earning Date | 03-13-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.50% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | $57.37 | ★ $23.96 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.25 | $4.06 |
| 52 Week High | $37.00 | $19.65 |
| Indicator | PBT | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 64.00 | 54.24 |
| Support Level | $32.75 | $10.82 |
| Resistance Level | N/A | $19.60 |
| Average True Range (ATR) | 0.86 | 0.79 |
| MACD | -0.10 | -0.38 |
| Stochastic Oscillator | 62.75 | 45.57 |
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.